The Board of Directors of the Company at their meeting held today approved the Standalone Unaudited Financial Results of the Company for the third quarter and nine months ended on31st December ....
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
BDH Industries' Board approved its Q3 FY26 (Oct-Dec 2025) and nine-month standalone unaudited results on 11th February 2026. Revenue from operations jumped to ₹2,933.89 lakhs in Q3 FY26, up sharply from ₹1,619.63 lakhs in Q3 FY25 — roughly 81% year-on-year growth. For the nine months, revenue rose to ₹6,692.23 lakhs vs ₹4,868.67 lakhs in the prior year period, about 37% growth. Profit after tax for Q3 stood at ₹348.90 lakhs (vs ₹280.90 lakhs, ~24% higher), with EPS of ₹6.06 vs ₹4.88. The Pharmaceuticals segment remains the key driver, contributing ₹2,919.74 lakhs of segment revenue in Q3, while Renewable Energy remained marginal at ₹14.15 lakhs. Statutory auditors CLB & Associates issued an unmodified limited review report.
Strong topline growth driven by the Pharmaceuticals segment should be viewed positively by shareholders, though profit margins compressed versus the year-ago quarter. Investors should watch whether the revenue surge sustains into Q4 and whether margin pressure is a temporary effect of higher input costs.